Business

Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis

Novartis

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis. The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara® * (ustekinumab) in psoriasis [1],[2]. The updated label also includes use of Cosentyx to treat moderate-to-severe scalp psoriasis[1]

Roche acquires mySugr to form a leading open platform for digital diabetes management

Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally, mySugr is one of the leading mobile diabetes platforms in the market and will become an integral part of Roche's new patient-centered digital health services platform in diabetes care.

Sanofi and Regeneron announce approval of Kevzara® (sarilumab) to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union

Sanofi

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) has granted marketing authorization for Kevzara® (sarilumab) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to - or who are intolerant to - one or more disease modifying anti-rheumatic drugs (DMARDs),

Roche's emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors

Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data from the primary analysis of the phase III HAVEN 1 study in adults and adolescents and interim analysis of the phase III HAVEN 2 study in children evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) for the treatment of haemophilia A with inhibitors to factor VIII.

New promising clinical trial management company coming to Germany

Data MATRIX

Data MATRIX has joined the Bavarian biotech cluster and open its' German office for international clients. Data MATRIX is a qualified provider for software, data management and biostatistics services for clinical trials. It is now introducing to the European market its' EDC/IWRS and CTMS products, based on the unique approach to software and high quality standards from Russian developers.

Merck Foundation established

Merck

Merck, a leading science and technology company, today announced the establishment of the Merck Foundation. Through this foundation Merck combines many of its corporate responsibility activities under one roof and considerably expands its scope to address health, social and economic challenges of the 21st century.

The made-in-Italy fast-track acceleration program dedicated to projects in life science

ZCube, Research Venture of the pharmaceutical group Zambon, announced the second edition of Open Accelerator, the made-in-Italy fast track acceleration program dedicated to projects in life science fields. Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that following a selection could receive a seed investment of up to a maximum of 100.000 EUR for each project.

Business

More Pharma News ...